Efficacy and safety of topical nicotinamide in treatment of discoid lupus erythematosus
Cutaneous lupus erythematosus is a term for a group of autoimmune diseases that affect the skin's connective tissues. Most people with cutaneous lupus erythematosus have a type called discoid lupus erythematosus. Current treatments for DLE are hard and not always effective. They can also be ver...
Saved in:
| Published in | International journal of health sciences pp. 7376 - 7387 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
08.08.2022
|
| Online Access | Get full text |
Cover
Loading…
| Summary: | Cutaneous lupus erythematosus is a term for a group of autoimmune diseases that affect the skin's connective tissues. Most people with cutaneous lupus erythematosus have a type called discoid lupus erythematosus. Current treatments for DLE are hard and not always effective. They can also be very expensive, off-label, or hard to get (like antimalarials due to COVID-19 outbreaks). Nicotinamide, which is also called niacinamide, is a form of vitamin B3 that dissolves in water (niacin). Nicotinamide could be used to treat skin lesions caused by lupus because it has more than one effect. On 20 people, we did a prospective randomized clinical trial. The data that was gathered showed that topical Nicotinamide can be used to treat DLE as an addition to other treatments, with good cosmetic results and few side effects. Topical Nicotinamide at a concentration of 4% is more effective than a concentration of 2%, but it causes more irritation. We need more tests with longer-term therapy, longer follow-up periods, and bigger sample sizes. |
|---|---|
| ISSN: | 2550-6978 2550-696X |
| DOI: | 10.53730/ijhs.v6nS5.11621 |